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Chemokines and their receptors have become significant factors in atherosclerosis research. CXCL16 
is a multifunctional agent located on a separate locus to all other known chemokines and binds only 
to its “unique” receptor named CXCR6. As a scavenger receptor, adhesion molecule, and chemokine, 
it quickly became an interesting target in atherosclerosis research as all its functions have a role in 
vascular pathology. The investigation of the role of CXCL16 in atherosclerosis, although shown in in 
vitro studies, animal knockout models, and CXCL16 gene polymorphisms, haplotypes, and circulat-
ing levels, still shows puzzling results. Genetic and epigenetic studies have just scratched the surface 
of research necessary for a better assessment of the significance and perspective of this marker in 
plaque development and progression. In this review, we will summarize current knowledge about 
CXCL16 in atherosclerosis. Additionally, we will point out the importance of bioinformatics tools 
for the detection of potentially new CXCL16 regulatory networks through microRNA activity. This 
review aims to provide a better understanding of the underlying mechanisms, define more specific 
biomarkers, and discover new therapeutic targets.
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1. Introduction
Research in the field of atherosclerosis identified 
chemokines and their receptors as important media-
tors of atherosclerotic plaque formation. Some of 
them are markers of disease progression, so there is a 
tendency to make them candidates for therapeutic 
intervention in both the prevention of atherogenesis 
and treatment of atherosclerosis1, 2). Because CXC 
chemokine ligand 16 (CXCL16) is described as a scav-
enger receptor, adhesion molecule, and chemokine, it 
quickly became interesting target in atherosclerosis 
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research as all its functions have a role in atherogene-
sis3). However, its role in atherosclerosis is not straight-
forward as assumed. Taking all the described functions 
of CXCL16 into consideration, we see a dual function 
of this molecule as it may be both proatherogenic and 
antiatherogenic depending on its role in different 
blood vessel compartments and the stage of athero-
sclerosis4, 5).
2. CXCL16
2-1. CXCL16: Unique Chemokine on Separate gene 
Locus
There are four subfamilies of chemokines 
described so far based on the arrangement of N-termi-
nal cysteines. They include C, CC, CXC, and CX3C, 
where X represents an amino acid residue other than 
cysteine6, 7). CXCL16 is a multi-domain chemokine 
that exists in the transmembrane and in a soluble 
1013�������������������������������������
dendritic cells11, 25), smooth muscle cells18, 26, 27), T-cells28), 
and endothelial cells3, 18, 26).
Studies that investigated the regulation of CXCL16 
gene expression by proinflammatory stimuli in endo-
thelial smooth muscle cells, human mononuclear cells, 
and atherosclerotic lesions of ApoE�/� mice have shown 
that the expression of CXCL16 mRNA is induced by 
INF� and TNF�, either separately or synergisti-
cally8, 18, 24, 27, 29). In ApoE�/� mice treated only with 
IL-18, which is known to be an inducer of INF�, a 
similar effect occurred as when they were subjected to 
direct INF� treatment. In this way, it was demon-
strated that CXCL16 mRNA expression could be also 
indirectly triggered30). All these findings reflect the 
complexity of the CXCL16 regulation pathway, which 
could be modified on different levels of the CXCL16 
gene regulatory network.
2-3. CXCL16: a Unique Molecule with “private” 
Receptor and Multiple Functions
The receptor for CXCL16 is a chemokine 
orphan, G protein-coupled receptor, first discovered as 
an HIV/SIV coreceptor, termed Bonzo/TYMSTR/
form. The transmembrane form is a 30-kDa glycopro-
tein of 254 amino acids. It consists of an N-terminal 
signal sequence and a C-X-C motif chemokine domain, 
followed by a mucin stalk, hydrophobic transmem-
brane domain for binding and suspension, and cyto-
plasmic tail. The tail has a YXPV motif, which is a 
potential substrate for tyrosine kinase phosphorylation 
(Fig.1). The stalk is highly glycosylated at the serine 
and threonine residues, which probably provides pro-
tection against proteolytic cleavage and folding8-10). 
This domain also participates in CXCL16-mediated 
cell adhesion11). The described type of organization is 
a novelty in the C-X-C chemokine subfamily as it is 
very similar to C-X3-C fractalkine/neuroactin12, 13). 
CXCL16 also contains six cysteine residues in the che-
mokine domain9), which was a characteristic previ-
ously observed only in the CC chemokine family 
(Fig.1)14). This chemokine is also unique as it is located 
on chromosome 17p13, a separate locus to all other 
known chemokines9).
Transmembrane chemokines are synthesized as 
transmembrane molecules and are transported to the 
cell surface. The conversion of the transmembrane 
into its soluble form is performed by proteolytic cleav-
age15, 16). It was found that the disintegrin-like metal-
loproteinase ADAM-10 and TNF�-converting enzyme 
ADAM-17 cleave CXCL16 from the cell surface and 
release the soluble form17-20). While ADAM-10 medi-
ates both constitutive and inducible cleavage17, 18, 20), 
ADAM-17 seems to be involved only in the inducible 
shedding of CXCL1621). The position of the protease 
cleavage site in CXCL16 is not clearly determined, 
but it is probably located in the mucin stalk domain, 
above the cell membrane (Fig.2)9). Signaling path-
ways that facilitate the increased cleavage of CXCL16 
by ADAMs are still unknown3).
Recent studies showed that cleavage is not the 
only way of forming the chemokine soluble form, as 
was previously thought. An alternatively spliced iso-
form of CXCL16 found to be expressed by murine 
dendritic cells and transfected HEK293 cells was 
termed the CXCL16v isoform. This isoform was not 
expressed on the cell membrane but was secreted as a 
10 kDa protein, which had all proinflammatory abili-
ties as the transmembrane form of CXCL16 
(Fig.2)22).
2-2. CXCL16: Direct and Indirect Regulation
The expression of the CXCL16 chemokine was 
observed in various types of cells. Human monocyte-
derived macrophages express CXCL16 on activation 
and in atherosclerotic lesions10, 23-25). CXCL16 expres-
sion at the mRNA level was also confirmed in B-cells8), 
Fig.1. Four domains of CXCL16 chemokine.
1) C-X-C motif chemokine domain with N-terminal signal sequence, 
2) Mucin stalk, 3) Hydrophobic transmembrane domain, 4) Cyto-
plasmic tail with YXPV motif
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platelets43).
The soluble form of CXCL16 acts as a chemoat-
tractant for nearly all cells that express its “private” 
receptor, at least in vitro8, 9, 29, 44). As this type of che-
motactic guidance of inflammatory cells into the 
blood vessel intima depicts another critical step of the 
plaque evolution process45), there was a presumption 
that the impaired levels of circulating CXCL16 could 
STRL33.31-33). It was named as CXCR6 according to 
chemokine and receptor nomenclature34). The interac-
tion between CXCL16 and CXCR6 is unique as it is 
shown that this chemokine does not bind to any other 
known chemokine receptor8). CXCR6 is expressed in 
smooth muscle cells35), dendritic cells36), B cells29, 37), 
macrophages38), natural killer T cells, bone marrow 
cells, CD4� and CD8� T cells8, 9, 25, 37, 39-42), and 
Fig.2. The role of CXCL16 in T-cell migration and adhesion.
CXCL16 gene expression can be up-regulated by a number of inflammatory stimuli (e.g., IFN-�, TNF-�). Two alternatively spliced mRNA 
variants of the CXCL16 gene code for different functional CXCL16 protein isoforms: the transmembrane CXCL16 and soluble CXCL16v 
isoform. The metalloproteolytic cleavage of the transmembrane form of CXCL16 with ADAM10 and ADAM17 produces the soluble form of 
this chemokine. The two soluble isoforms induce the migration of T cells through an interaction with CXCR6. The subsequent firm adhesion 
of migrating T cells to the vascular wall is achieved with the synergistic activity of the CXCL16 transmembrane form and ICAM1 and 
VCAM1.
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ble to burst, making the environment of advanced 
plaques prone to destabilization (Fig.3).
3. Role of CXCL16 in Atherosclerosis
3-1. CXCL16 and Atherosclerotic Plaque Forma-
tion: Atherogenesis vs. Atheroprotection
It has been shown that CXCL16 mRNA and 
protein expression are significantly upregulated in cor-
onary and carotid atherosclerotic plaques than in 
healthy blood vessels24). The immunohistochemical 
staining of carotid plaques confirmed a higher expres-
sion of CXCL16 and CXCR6 in plaque regions rich 
in macrophages and T cells as was expected for a scav-
enger receptor3, 23, 24). It was reported that human and 
mice smooth muscle cells express CXCL1627, 38), but 
this was not the case in rabbit arteries53), which poten-
tiates need and caution regarding a species-specific 
approach. The study conducted on rabbit lesion-prone 
sites of endothelium implies that CXCL16 is involved 
even in the initial stages of atherosclerosis53) and not 
only in advanced plaques. This abundance of CXCL16 
in atherosclerotic lesions observed in different cell 
types and in different stages of plaque development 
was a good reason to investigate the role of CXCL16 
in the pathogenesis of atherosclerotic plaques. Although 
a lot of studies focused on its detrimental effects, not 
cause the development of atherosclerosis.
This chemokine also has functions that are 
beyond leukocyte recruitment.10, 46). The dysfunction 
of blood vessel endothelium leads to its impaired per-
meability and the infiltration of circulating LDL to 
vessel intima. Infiltrated LDL binds to extracellular 
matrix within the arterial wall and becomes modified 
in different ways, e.g., oxidized47, 48). Oxidized LDL 
(oxLDL) is the target of different scavenger receptors 
expressed on the macrophages in the arterial intima. 
The ingestion of oxLDL by macrophages appears to 
play a key role in foam cell transformation and subse-
quent atherosclerotic progression5). It was described 
that CXCL16 also has scavenging properties besides 
chemotaxis and adhesion and therefore, could pro-
mote foam cell formation10). These lipid-rich cells 
release cytokines, growth factors, matrix metallopro-
teinases (MMPs), reactive oxygen species (ROS), and 
tissue factors, which lead to inflammation, vascular 
remodeling, and plaque vulnerability49).
It was shown that CXCL16 also has proangio-
genic activity by inducing the proliferation of human 
umbilical vein endothelial cells (HUVECs)50). It is 
known that angiogenesis in the early stages of plaque 
development promotes stabilization as it feeds intimal 
cells51, 52). However, in the later stages of plaque devel-
opment, these small, fragile blood vessels are suscepti-
Fig.3. Potential roles of CXCL16 in the development of atherosclerosis.
The transmembrane form of CXCL16 acts as a scavenger receptor in addition to its role in adhesion. The scavenging of oxLDL particles in 
the blood vessel intima is the main cause of macrophage to foam cell transformation and formation of an atherosclerotic lipid-rich core. Foam 
cells also produce different factors that could further destabilize atherosclerotic plaques, such as ROS, MMPs, growth factors, and cytokines. 
Soluble CXCL16 may direct monocyte migration, smooth muscle cell proliferation, and plaque angiogenesis, which all contribute toward 
plaque evolution and stability.
1016 ����������������
cific differences in CXCL16 functioning have already 
been observed in different animal models. This is the 
reason why these data have to be evaluated and veri-
fied in further functional studies, and in different ani-
mal models and human clinical studies.
3-2. Potential Role of CXCL16 in Atherothrombo-
sis
Under physiological conditions, platelet adhesion 
to the vascular wall followed by platelet activation is 
crucial for primary hemostasis. On the other hand, 
they could also be the processes underlying acute arte-
rial thrombotic occlusion at the regions of atheroscle-
rotic plaque rupture, which is a pathophysiological 
mechanism causing myocardial infarction and isch-
emic stroke. It is known that endothelial cells play a 
major role in vascular physiology, so abnormalities in 
their structure and function may contribute to throm-
bosis58). Therefore, the culture of HUVECs became 
one of the best in vitro models in vascular pathology 
research50, 53, 59, 60). A recent study has shown for the 
first time that CXCL16 increases platelet adhesion to 
the HUVEC monolayer under conditions of high 
arterial shear stress in in vitro flow chamber experi-
ments43). Moreover, the authors verified this process in 
vivo after carotis ligation by intravital microscopy. 
They also found that CXCL16 triggers platelet activa-
tion and aggregation in response to low-dose ADP 
activation. Platelet adhesion, activation, and aggrega-
tion are major mechanisms underlying thrombotic 
artery occlusions. Therefore, the authors concluded 
that CXCL16 expression in atherosclerotic lesions and 
release from inflammatory cells could be an additional 
local proadhesive stimulus for circulating platelets that 
could lead to increased platelet adhesion at the sites of 
vascular injury. Thus, CXCL16 could play a decisive 
role in linking inflammatory vascular diseases and 
thrombosis43).
4. CXCL16 gene Polymorphisms 
and microRNA
4-1. CXCL16 gene Polymorphisms and Circulating 
Levels as Potential Biomarkers in Atherosclerosis
Research of the CXCL16 gene variants in athero-
sclerotic vascular pathology (Table 1) has also pro-
vided ambiguous results. The most investigated single-
nucleotide polymorphism (SNP) A181V (rs2277680) 
is located in the fourth exon of the CXCL16 gene. In 
this non-synonymous polymorphism, alanine is sub-
stituted with valine at codon 181 located in the mucin 
stalk. An earlier study showed that although there was 
no significant difference in allele frequency between 
all described CXCL16 as strictly proatherogenic factor.
In animal models for atherosclerosis, it was 
shown that the deletion of CXCL16 and CXCR6 
demonstrates different effects. CXCL16 knockout 
mice developed larger plaques in both the aortic arc 
and root compared with atherosclerotic mice without 
CXCL16 disruption. The authors proposed that the 
reason for increased lesion size could be the affected 
clearance of apoptotic cells by CXCL16, which is in 
line with its possible atheroprotective role54). Earlier, 
the general opinion was that scavenger receptors are 
highly atherogenic by producing massive cholesterol 
depositions in the blood vessel intima23, 55). Today, it is 
known that scavenger function also regulates apop-
totic cell clearance, thus maintaining vascular wall 
homeostasis56). However, further in vitro experiments 
showed that macrophages from CXCL16-deficient 
mice internalize apoptotic thymocytes equally well 
compared with those in control mice, which brought 
into question the proposed atheroprotective mecha-
nism. The authors suggested the role of CXCL16 in 
oxLDL scavenging as an additional mechanism for the 
observed atheroprotective role. They revealed that 
macrophages originating from CXCL16-deficient mice 
exhibit a significant decrease in the internalization of 
oxLDL54). In contrast, another in vitro study demon-
strated that oxLDL uptake mediated by CXCL16 plays 
a critical role in foam cell formation, which makes it 
proatherogenic57). It is clear that these different find-
ings impose the need for more functional and in vivo 
studies to elucidate if there is a dual role of CXCL16 
in atherosclerosis.
Data regarding the role of CXCR6 in atheroscle-
rosis mainly propose its proatherogenic effect, but 
again, the mechanism of its action is not clearly 
defined. ApoE�/� CXCR6�/� mice did not express any 
significant pathological difference in the aortic arch 
compared with control animals38), where CXCR6-
deficient homozygotes showed less accumulation of 
certain lymphocytes and macrophages into the aorta’s 
wall38). These findings suggest that CXCR6 has a pro-
atherogenic influence, but the paradox remains, as the 
earlier mentioned CXCL16-deficient mice also had less 
CXCR6 positive cells in lesions, but larger plaques54).
The reason for the contradiction of the results 
could be explained in different ways. The multiple 
functions of CXCL16, such as adhesion, chemotaxis 
and scavenging, participate in both proatherogenic 
and atheroprotective processes and have different rela-
tive contribution to atherogenesis. Therefore, in dif-
ferent time courses of disease development and under 
different stimuli, certain functions could predominate 
and override others. On the other hand, species-spe-
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plasma CXCL16 levels between the T123V181 and 
I123A181 haplotypes. In addition, we performed bio-
informatics analysis by the information-spectrum 
method67) to investigate the potential effects of these 
haplotypes on CXCL16–CXCR6 interactions. We 
found that the same rare haplotype, T123V181, has 
the ability to significantly change the CXCL16–
CXCR6 interaction than the wild-type I123A18166). 
This result should be functionally evaluated and con-
firmed, while the effects of these haplotypes on 
mRNA levels should be confirmed in a representative 
number of tissue specimens. The largest angiography-
based case-control study comprising 1175 patients with 
coronary artery disease (CAD) and 850 controls was 
conducted in the Chinese Han population. Five SNPs 
were evaluated for their association with increased risk 
of CAD and CXCL16 plasma levels, including the 
previously mentioned rs2277680 (A181V)68). The 
only SNP that showed a significant association with 
CAD was the rs3744700 (T/G) located in a fourth 
intron of CXCL16, where the T allele, marked as 
ancestral, is substituted with the G allele. The G allele 
frequency was significantly higher in the patients with 
CAD and individuals homozygous for this allele had 
significantly increased susceptibility to CAD than the 
T allele carriers. The detailed in silico analysis of 
intron 4 led to a finding that this polymorphism 
affects the GATA-binding site and therefore, probably 
influences CXCL16 gene transcription68). The GG 
genotype was also associated with significantly higher 
plasma levels of CXCL16 than other genotypes64, 68). 
It is still debatable whether this SNP affects CXCL16 
expression or splicing as it was shown that intronic 
post MI patients and control group, the less frequent 
V allele is independently associated with an increased 
mean percentage of stenosis in the same group of 
patients. In an additional group of patients undergo-
ing percutaneous transluminal coronary angioplasty 
(PTCA) with stent implantation, the same allele is 
associated with a smaller minimal luminal diameter of 
coronary arteries before PTCA61). It was suggested 
that this amino acid substitution changes the cleavage 
site and thus increases the amount of soluble 
CXCL16, which could stimulate the chemotaxis of T 
cells and the proliferation of smooth muscle cells, and 
contribute to atherosclerosis61). Later studies showed 
that the circulating levels of CXCL16 are better pre-
dictive markers for atherosclerosis and its end points 
(myocardial infarction, stroke, and mortality)62, 63) 
than the A181V polymorphism64). Further, it was shown 
that the A181V polymorphism influences the func-
tionality of CXCL16 in a way that the V allele inhibits 
monocyte adhesion; however, it has not been associ-
ated with susceptibility to human coronary heart dis-
ease65). Recently, we performed a preliminary study 
investigating the I123T (rs1050998) polymorphism 
(also located in the mucin stalk domain) and A181V 
polymorphism haplotypes in carotid atherosclerosis. 
Although CXCL16 mRNA expression in carotid 
plaques showed no significant difference according to 
haplotypes, the T123V181 haplotype was significantly 
and independently associated with carotid atheroscle-
rosis plaque occurrence compared with the more fre-
quent I123A18166). We also analyzed the soluble 
plasma levels of CXCL16 according to haplotypes, but 
only in controls. We found no significant difference in 
Table 1. CXCL16 SNPs associated with vascular pathology
SNP Observed effects Ref.
rs2277680 (A181V) The V allele was independently associated with an increased mean percentage of stenosis 
in patients with MI and with a smaller minimal luminal diameter of coronary arteries 
before PTCA.
[61]
rs2277680 (A181V) The V allele inhibits monocyte adhesion by CXCR6. [65]
rs2277680 (A181V) and 
rs1050998 (I123T)
The T123V181 haplotype was significantly and independently associated with carotid 
atherosclerosis plaque occurrence than the more frequent I123A181.
[66]
The T123V181 haplotype has the ability to significantly change the CXCL16–CXCR6 
interaction compared with the wild type I123A181.
rs3744700 (T/G) Homozygous individuals for the G allele had a significantly increased susceptibility to 
CAD than the T allele carriers.
[68]
The GG genotype was associated with significantly higher CXCL16 plasma levels in both 
patients and controls.
Abbreviations: MI, myocardial infarction; CAD, coronary artery disease; PTCA, percutaneous transluminal coronary angioplasty
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important domain of miRs for mRNA targeting is the 
miR seed region that spans from nucleotide 2 to 7 in 
its 5´ end, but it is also known that the rest of the 
mature miR sequence helps target recognition78). It 
was predicted that more than 60% of human protein-
coding genes contain at least one conserved miR tar-
get site. Therefore, it is not surprising that the dysreg-
ulation of certain miRs often leads to the development 
of various human diseases. Cardiovascular diseases are 
among them. Because there are already thorough reviews
that summarize current knowledge about miRs impli-
cated in atherosclerosis susceptibility, development, and 
progression81-88), we will focus on the part of athero-
sclerosis pathology where different miRs could poten-
tially alter vascular physiology by the direct or indirect 
regulation of CXCL16 gene expression.
There is a lot of evidence that miRs play a very 
important role in atherosclerosis and lipoprotein 
metabolism through mechanisms that affect endothe-
lial integrity, macrophage inflammatory response to 
atherogenic lipids, vascular smooth muscle cell prolif-
eration, and cholesterol synthesis89). Recent findings 
describe a linear pathway induction of miR-221 by 
Staphylococcal nuclease domain-containing protein 1 
and NFkB and the subsequent activation of CXCL16 
as an angiogenic factor in hepatocellular carcinoma90). 
The authors assumed that there is a negative regulator 
of CXCL16 gene expression, which is a target of miR-
221. They also suggested that the described downreg-
ulation of the tissue inhibitor of metalloproteinase-3 
mediated by miR-221 increases the expression of 
ADAM10 and ADAM1791) and thus, enhances the 
production of the angiogenic form of CXCL16, the 
soluble form90). If these results could be extrapolated 
to blood vessel pathology, the induction of CXCL16 
by miR-221 could contribute, as previously described, 
to plaque stability or thrombotic prognosis via the for-
mation of the vasa vasorum, for example. Although 
angiogenesis in the early stages of plaque formation 
has atheroprotective effects because it prevents the 
apoptosis of vascular smooth muscle cells and forma-
tion of lipid rich core, in advanced atherosclerosis, it 
could have a completely different effect. In advanced 
atherosclerosis, angiogenesis results in blood vessels 
becoming more fragile and susceptible to burst92). 
However, the simple prediction of miR-221 role in 
vascular pathology is not possible due to cell-specific 
functions. It was shown that although highly expressed 
in both vascular smooth muscle cells and endothelial 
cells, the function of miR-221 differs in these cells. In 
vascular smooth muscle cells, it has proliferative and 
migratory effects. On the other hand, it has antimigra-
tory and antiproliferative effects in endothelial cells93). 
variations can influence gene splicing and could repre-
sent the functional markers of human diseases68, 69). At 
the end, the SNP rs3744700 could be a neutral marker 
that resides in linkage disequilibrium with another, 
rare, functional polymorphism in the CXCL16 gene 
or with a mutation of another neighboring gene or 
even locus located in a distant region of the genome68). 
As the discovery of the rs3744700 polymorphism 
effects are a novelty, it is necessary to validate these 
results in other populations due to environmental and 
ethnical differences.
Several studies that evaluated CXCL16 circulat-
ing levels as a potential biomarker of vascular pathol-
ogy also provided inconsistent results. While two stud-
ies showed that the lower concentrations of CXCL16 
could correlate with CAD and acute coronary syn-
drome70, 71), one study claimed that patients with 
CAD had higher CXCL16 levels72) and another one 
did not find any association of serum CXCL16 with 
CAD in patients with rheumatoid arthritis73). These 
conflicting findings necessitate additional clinical stud-
ies on larger study groups and in different populations. 
Although CXCL16 circulating levels were shown to be 
an independent predictor of long-term mortality and 
heart failure development in patients with acute coro-
nary syndrome, the combination with additional inde-
pendent biomarkers in a multimarker panel makes it 
even more informative74). CXCL16 may also be a 
promising biomarker for idiopathic pulmonary arte-
rial hypertension as its plasma levels are significantly 
increased in patients than in healthy controls75). This 
could be due to right ventricular remodeling and 
inflammation in pulmonary circulation. It was described 
that myocardial CXCL16 expression is enhanced in 
experimental and clinical heart failure and that 
CXCL16 promotes the matrix remodeling of the ven-
tricles by stimulating MMP activity in cardiomyocytes 
and fibroblasts in vitro76). The increased serum levels 
of CXCL16 also have the potential to become an 
independent biomarker for atherosclerotic ischemic 
stroke, particularly in large arteries77).
4-2. CXCL16 and microRNA
MicroRNAs (miRs) are approximately 22 nucle-
otides long RNAs constituting a dominant class of 
small non-coding RNAs in most somatic tissues78). 
During the RNA silencing process, the base pairing of 
miRs with target mRNA guides the RNA-induced 
silencing complex (RISC), which subsequently recruits 
different factors promoting translational repression, 
mRNA deadenylation, and mRNA degradation79). The 
target sites of miRs are most often located in the 3´ 
untranslated region (UTR) of mRNA80). The most 
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Nowadays, multiple miR target prediction algo-
rithms are developed based on different criteria such 
as target conservation, seed-target complementarity, 
seed pairing stability, free energy of duplex, etc.99-106). 
We decided to use the ComiRNet database of pre-
dicted miR regulatory network107) to search for the 
potential targets of our miRs in the CXCL16 3´ UTR 
sequence. Using ComiRNet, we found that certain 
miRs that we previously associated with early athero-
sclerotic plaque (miR-99, miR-100, miR-140, miR-
145, miR-22, miR-339, and miR-34c) and advanced 
plaque (miR-146b, miR-127, and miR-21)96) have their 
target sites in the CXCL16 mRNA 3´ UTR sequence 
(Fig.4). Although some of these miRs have already 
been described as atherosclerosis contributors in a pos-
itive or negative context,96) none of them have under-
gone functional study for the CXCL16 interaction. 
Therefore, further research on the role of CXCL16 in 
atherosclerosis should take into account different miRs 
and their expression in the different stages of athero-
sclerosis.
According to crosslinking, ligation, and sequenc-
ing of hybrids (CLASH), it was discovered that two 
Other findings of angiogenesis inhibition by miR-221 
in HUVECs60, 94, 95) could demonstrate how it is diffi-
cult to extrapolate data about miR-221 in different 
tissues. Recently, by an in silico analysis, we found 
miR-221 to have a role in the advanced stages of ath-
erosclerosis96).
Our recent study, which was based on the com-
putational analysis of miRs associated with the early 
and advanced stages of atherosclerosis, revealed poten-
tially characteristic miRs for these two stages. Some of 
them were already described in terms of atheroprotec-
tive or atherogenic function, but some were a novelty 
in atherosclerosis research96). Generally, knowledge 
about interactions between different miRs and 
CXCL16 in atherosclerosis or any other pathology is 
very scarce. Therefore, for the purpose of this review, 
we wanted to test if the most significant miRs from 
our study have potential target sites in the CXCL16 
mRNA 3´ UTR. The impaired function of these post-
transcriptional regulators could highly affect the tem-
poral expression of CXCL16, and it was reported that 
the altered levels of this chemokine show different 
actions depending on the stage of the disease53, 54, 97, 98).
Fig.4. miRNAs from co-inertia analysis with potential target sites in the 3´ UTR of CXCL16, 
according to ComiRNet.
miRs associated with early and advanced atherosclerotic plaque in the co-inertia analysis were filtered 
using the ComiRNet database of miR target predictions to extract those with potential target sites in the 
3´ UTR of CXCL16.
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importance of chemokines in atherogenesis and the 
progression and destabilization of atherosclerotic 
plaques. The CXCL16 chemokine with its unique 
receptor expresses a high degree of complexity through 
its multiple functions, different forms, and not clearly 
defined nature during the course of the chronic inflam-
matory milieu of atherosclerosis. All heterogeneous 
data from association, knockout, and gene expression 
studies conducted on different blood vessel wall com-
partments, in different atherosclerotic phenotypes, 
and in different animal models require additional 
research. Further research should be carefully designed 
to take into account the temporal and spatial approach, 
species-specific differences in CXCL16 functions, cell 
specificity, and complex genetic and epigenetic net-
works. Thorough analysis of the CXCL16 gene, hap-
lotype, and miRs could have the potential to reveal 
new disease pathways and new targets for therapeutic 
intervention. This kind of thorough research is a path 
toward identification of novel biomarkers as well as 
novel therapeutic targets in the future.
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